Recombinant protein vaccine stands up to SARS-CoV-2 variants

A study by researchers in Texas describes a mouse model in which a subunit vaccine with alum-CpG adjuvant was tested for its ability to induce a broadly neutralizing antibody response against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
A study by researchers in Texas describes a mouse model in which a subunit vaccine with alum-CpG adjuvant was tested for its ability to induce a broadly neutralizing antibody response against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).